A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Here’s an important clarification worth starting with: 5-Amino-1MQ isn’t a peptide at all, despite frequently being marketed and discussed alongside genuine peptides in the wellness space. It’s a small organic molecule that selectively blocks an enzyme called NNMT (nicotinamide N-methyltransferase), first characterized in a 2017 scientific study.
NNMT plays an interesting role in the body: it uses up two important cellular resources — SAM (the body’s primary methyl donor, needed for hundreds of processes) and nicotinamide (a building block for NAD+) — and elevated NNMT activity has been linked to obesity and metabolic dysfunction in research models. By blocking this enzyme, 5-Amino-1MQ is proposed to preserve these resources in fat tissue and shift cellular metabolism toward burning fat rather than storing it.
In diet-induced obese mice, blocking NNMT with this compound reversed obesity and improved glucose tolerance. A specific study using three-times-daily injections over 11 days documented reduced body weight, reduced food intake, reduced abdominal fat pad weight, and smaller fat cells in that animal model. It’s worth being completely direct here: none of this has been evaluated in humans. There are no published human clinical trials of any phase, no established safe human dose, and no human pharmacokinetic or safety data exists at all.
These pathways connect to NAD+ availability and mitochondrial biogenesis — both of which depend on niacin (vitamin B3, a direct NAD+ precursor), riboflavin, and magnesium (required for most ATP-dependent enzymatic steps).
5-Amino-1MQ is not FDA-approved for any indication, is not on the FDA’s 503A Bulk Drug Substances list, and has no legitimate compounding or clinical access pathway in current US practice. This page describes preclinical research findings only — it is not a claim about effects in humans and not an offer to treat any condition.
5-Amino-1MQ remains in preclinical research, with no completed controlled human clinical trials. Animal studies have examined its NNMT-inhibiting effect and associated changes in body composition in those models. This describes preclinical findings, not a demonstrated human outcome.
Its mechanism (NNMT inhibition) is documented to preserve intracellular NAD+ availability, connecting it mechanistically to the same metabolic pathways NAD+ itself is involved in.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
